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DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer. In this issue of Cell,
Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict
the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized
therapy for patients with pancreatic cancer.The outcomes for pancreatic ductal
adenocarcinoma (PDAC) are dismal and
have not improved much despite the
accumulating knowledge on its biology.
One important clinical observation is
that, despite the overall poor prognosis,
the patterns of treatment failure in
PDAC vary significantly. Some patients
succumb to overwhelming local tumor
burden due to the highly proliferative
nature of their cancer cells, while for
others, widespread metastases are the
major issue. While it is clearly important
to tailor the therapeutic options accord-
ingly, we are in need of reliable clinical
biomarkers for distinguishing these two
groups. Hingorani and colleagues set
out to address this issue using a geneti-
cally engineered mouse model (GEMM)
approach (Whittle et al., 2015). Through
careful analysis of Dpc4 haploinsufficient
mice, they found that RUNX3 expression,
together with the DPC4/SMAD4 level,
could potentially help to inform such clin-
ical decisions.
The cardinal mutation in PDAC is acti-
vated KRAS (>95%) occurring at the
earliest stages of the disease, whereas
mutations in DPC4/SMAD4 are thought
to facilitate the progression of PDAC.
Indeed, loss of Smad4 protein correlates
with worse clinical outcomes (Biankin
et al., 2002), and studies in mousemodels
have confirmed that loss of Dpc4 confers
a metastatic phenotype (Bardeesy et al.,
2006). To explore the underlying biology,
Whittle et al. generated KPDC mice
that harbor an activated Kras allele
(KrasLSL-G12D/+), a dominant-negative
Trp53 allele (Trp53LSL-R172H/+), and a het-
erozygous knockout of Dpc4 (Dpc4fl/+),
all driven by the pancreas-specific Ptf1a-Cre, and compared them to the KPC
mice with mutations in Kras and Trp53
but wild-type Dpc4. As expected, KPDC
mice developed more aggressive tumors,
leading to increased mortality compared
to the KPC counterparts. Surprisingly,
however, KPDC tumors were only aggres-
sive in growth at the primary site but were
lessmetastatic than the KPC controls. It is
worth noting that a prior study from this
group has shown that, in the absence of
concurrent p53 mutations, heterozygous
mutation of Dpc4 altered the differentia-
tion state of ductal precursor lesions
initiated by oncogenic Kras from pancre-
atic intraepithelial neoplasia (PanINs) to
mucinous cystic neoplasms (MCNs) (Izer-
adjene et al., 2007). Subsequent progres-
sion to invasive PDAC involved loss of
heterozygosity of the wild-type Dpc4
allele and mutations in p53 or p16. While
these cancers spontaneously developed
the same cardinal mutations found in con-
ventional PanIN-to-PDAC, the MCN-to-
PDAC route led to a lower metastatic
burden, consistent with the improved
prognosis seen in patients with this route
(Wilentz et al., 1999). The authors there-
fore hypothesized that the chronological
order in which key oncogenic mutations
occur might affect the ensuing pathology.
In the current study, they have demon-
strated that, even in the face of concur-
rent p53 mutation, which now elicits the
usual PanIN-PDAC multistep progres-
sion, a heterozygous mutation of Dpc4
continues to attenuate the metastatic
potential of PDAC.
Further investigation revealed that
Dpc4 was not the whole story. The
authors found that Runx3 expression
was elevated by 36-fold in highly meta-Cell 1static KPC mice, compared to the
locally destructive, albeit oligo-metastatic
KPDC mice. Moreover, forced overex-
pression of Runx3 could override the
metastasis-attenuating effect of Dpc4
haploinsufficiency in KPDC cells, enabling
the formation of lungmetastases in immu-
nocompromised mice. How Runx3 pro-
motes metastasis remains to be fully
elucidated. Another intriguing question
pertains to the modulation of Runx3 levels
byDpc4/Smad4 gene dosage during can-
cer development.
Although these studies were primarily
performed inmice, the findings are poten-
tially valuable for informing clinical deci-
sions. Remember that not all PDAC
patients die from metastatic disease.
Indeed, many of them suffer great
morbidity and mortality from biliary
sepsis, gastric outlet obstruction, and
acute venous occlusion caused by local
tumor growth (Iacobuzio-Donahue, et al.,
2009). A predictive measure for the devel-
opment pattern of PDAC is therefore
essential for tailoring treatment. DPC4/
SMAD4 has shown such promise (Crane
et al., 2011), and the expression of
Smad4 protein is being tested prospec-
tively as a predictive marker of PDAC
behavior in the phase II randomized
trial RTOG 1201, examining the effi-
cacy of dose-escalated chemoradiation
versus conventional chemoradiation or
chemotherapy alone. However, currently,
Smad4 levels are determined by immuno-
histochemistry, and the results are cate-
gorized as a dichotomous output—either
positive or negative. Since this technique
cannot distinguish subtle changes of
Smad4 expression, including heterozy-
gous DPC4/SMAD4 deletion, it is not61, June 4, 2015 ª2015 Elsevier Inc. 1245
Figure 1. Runx3 Could Improve the Utility of Smad4 as a Biomarker of Pancreatic Cancer
Biology
Patients with the combination of detectable Smad4 expression and a low level of Runx3 may benefit from
aggressive local therapy because of the proliferative nature of the tumors. In contrast, tumors with
undetectable Smad4 or a high level of Runx3 tend to be highly metastatic, and the therapeutic regime
should be tailored accordingly.surprising that positive Smad4 expression
alone has not been widely used for pre-
dictive purposes (Winter et al., 2013).
The study from Whittle et al. proposed
a potential solution of using Runx3
expression in tumor cells for predicting
the behavior of Smad4-positive tumors
(Figure 1). For clinical applications, this
idea needs to be further tested in multiple
retrospective data sets. It is also impor-
tant to understand whether the predictive
power would also apply to common com-1246 Cell 161, June 4, 2015 ª2015 Elsevier Inbinations of PDAC mutations that were
not explicitly examined in this study,
such as those involving CDKN2A. None-
theless, identifying RUNX3 as a metasta-
tic switch in this context is encouraging,
and with this knowledge, oncologists
could personalize therapeutic ap-
proaches by treating locally aggressive
tumors with higher radiation doses and/
or more liberal criteria for surgery but
prioritizing chemotherapy for those with
a metastatic potential.c.REFERENCES
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In this issue of Cell, Pelechano et al. report that sequencing of mRNA decay intermediates shows
surprisingly tight coupling of a major decay pathway to the movement of the last translating ribo-
some, revealing stress- and starvation-dependent modulation of translation elongation.Messenger RNA lives an eventful life—
each molecule is transcribed from DNA
and then may be spliced, polyadenylated,
modified, exported, transported, andtranslated before succumbing to degra-
dation. Stages in the mRNA life cycle
often overlap in important ways: splicing
acts as a co-transcriptional quality con-trol checkpoint (Chathoth et al., 2014),
mRNA-ribosome complexes are cotrans-
lationally localized to membranes by the
signal recognition particle, and mRNA is
